Bobin Dubigeon Christine

Dr. Bobin Dubigeon Christine


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
BCBobin Dubigeon Christine
Bobin Dubigeon Christine
HLHuyen Trang Luu
Huyen Trang Luu
SLSébastien Leuillet
Sébastien Leuillet
SLSidonie Lavergne
Sidonie Lavergne
TCThomas Carton
Thomas Carton
JBJean-Marie Bard
Jean-Marie Bard
The intestinal microbiota plays an essential role in many diseases, such as obesity, irritable bowel disease (IBD), and cancer. This study aimed to characterize the faecal microbiota from early-stage breast cancer (BC) patients and healthy controls. Faeces from newly diagnosed breast cancer patients, mainly for an invasive carcinoma of no specific type (HR+ and HER2−), before any therapeutic treatment and healthy controls were collected for metabarcoding analyses. We show that the Shannon index, used as an index of diversity, was statistically lower in the BC group compared to that of controls. This work highlights a reduction of microbial diversity, a relative enrichment in Firmicutes, as well as a depletion in Bacteroidetes in patients diagnosed with early BC compared to those of healthy women. A tendency towards a decreased relative abundance of Odoribacter sp., Butyricimonas sp., and Coprococcus sp. was observed. This preliminary study suggests that breast cancer patients may differ from healthy subjects in their intestinal bacterial composition.

1 November 2015 in Clinical Biochemistry
Verified
Journal Article
Closed access
BCBobin Dubigeon Christine
Bobin Dubigeon Christine
ALArmelle Lefrançois
Armelle Lefrançois
JCJean-Marc Classe
Jean-Marc Classe
MJMarie-Pierre Joalland
Marie-Pierre Joalland
JBJean-Marie Bard
Jean-Marie Bard

1 December 2011 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
BCBobin Dubigeon Christine
Bobin Dubigeon Christine
AHAlexandra Heurgue-Berlot
Alexandra Heurgue-Berlot
OBOlivier Bouché
Olivier Bouché
MAMarie-Bernadette Amiand
Marie-Bernadette Amiand
CGChantal Le Guellec
Chantal Le Guellec
JBJean-Marie Bard
Jean-Marie Bard
A simple liquid chromatography-mass spectrometry method was developed and validated for quantification of sorafenib (Nexavar) in human plasma. After a solid-phase extraction procedure, the separation was performed within 2 minutes using an isocratic flow of a mobile phase consisting of formic acid/acetonitrile applied on a C18 analytical column. The analyte was detected by mass spectrometry in the single-ion monitoring mode. The method was validated according to the recommendations of the US Food and Drug Administration. The method was linear (r² > 0.99) between 10 and 10,000 ng/mL. The lower limits of detection and quantification were 5 and 10 ng/mL, respectively. Within-day and between-day imprecisions were less than 10.4%, and inaccuracy did not exceed 8.7%. The mean extraction recovery was 92.2%. The method also provided satisfactory results in terms of time stability and dilution integrity. Sorafenib plasma concentrations of the studied patient ranged between 1831 and 3459 ng/mL. This new technique is rapid, sensitive, and was applied to the determination of sorafenib plasma concentrations in a patient undergoing hemodialysis. Our results indicate that sorafenib is not cleared from plasma by hemodialysis, although analysis should be delayed after dialysis to avoid erratic fluctuations.

5 June 2019 in Future Science OA
Verified
Journal Article
Open access
BCBobin Dubigeon Christine
Bobin Dubigeon Christine
MCMario Campone
Mario Campone
ERElsa Rossignol
Elsa Rossignol
ESEstelle Salaun
Estelle Salaun
MAMarie-Bernadette Amiand
Marie-Bernadette Amiand
JBJean-Marie Bard
Jean-Marie Bard
Aim: A rapid UPLC–MS/MS method for the determination of tamoxifen (TAM), N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma was validated, after a simple protein precipitation. ... Lay abstract Tamoxifen is a drug widely used in the treatment of hormone-dependent breast cancer. However, interindividual variations of drug concentration are described, according to the metaboliz...

24 December 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
BCBobin Dubigeon Christine
Bobin Dubigeon Christine
JBJean-Marie Bard
Jean-Marie Bard
TLTrang-Huyen Luu
Trang-Huyen Luu
FVFrançoise Le Vacon
Françoise Le Vacon
HNHassan El-Hassane Nazih
Hassan El-Hassane Nazih
We hypothesized that the role of microbiota in breast cancer relates to its influence on gut lipid metabolism. This was tested in an in vitro model combining MCF-7 and Caco-2 cells. A total of 32 women newly diagnosed for breast cancer before any treatment and 28 healthy women provided their stools. Bacterial DNA was amplified by qPCR targeting 16s rRNA specific to Bacteroidetes and Firmicutes phyla, Lactobacillales sp., Clostridium cluster IV, Faecalibacterium prausnitzii, Clostridium cluster XIVa, Roseburia intestinalis, Blautia sp., Lactonifactor longoviformis, Bifidobacterium sp., Coriobacteriaceae, Eggertella lenta, Escherichia, and Shigella. Fecal waters (FW) were quantified for short chain fatty acids (SCFA). Caco-2 cells grown on filter inserts were incubated apically with 10% FW for 24 h, and LXR, apolipoproteins AIV, and E gene expression were estimated by real time (RT) qPCR. Then, MCF-7 cells were incubated with the whole basolateral medium for 24 h, and their viability was estimated by 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) test. Regression models were used to determine the correlation between MCF-7 viability and bacteria relative abundance, Caco-2 cells lipid metabolism gene expression and stool composition, as well as microbiota composition and short chain fatty acids. Logistic regression models established disease odds ratios (OR) for MCF-7 viability and Caco-2 gene expression. The OR of MCF-7 viability was 1.05 (1.01–1.10) (OR (5th–95th), p = 0.04), while that of apo AIV gene expression was 0.63 (0.39–1.01), p = 0.055). Viability correlated with % Bifidobacterium sp. (21.18 ± 7.66, p = 0.008) and valerate (−2.849 ± 1.048, p = 0.009) (β ± s.d.). This study suggests that microbiota interacts with intestine cell lipid metabolism. Since these metabolites can reach breast cells by systemic circulation, we hypothesized that they may influence cancer disease.

22 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
BCBobin Dubigeon Christine
Bobin Dubigeon Christine
Loic CampionLoic Campion
Loic Campion
CBClémence Bossard
Clémence Bossard
ERElsa Rossignol
Elsa Rossignol
JFJean-Sebastien FRENEL
Jean-Sebastien FRENEL
JBJean-Marie Bard
Jean-Marie Bard
Background/Objectives: Nearly 10% of cancers could be prevented through dietary changes. In addition, breast cancer (BC) is the most common cancer in women worldwide. Inadequate diet may lead to several metabolic abnormalities, including metabolic syndrome (MS). The goal of our study is to evaluate the link between survival after BC and MS, as well as diet lipids and circulating lipids. Methods: This study was performed in an early-stage BC cohort (n = 73): MS, dietary lipids, and circulating biological parameters, including leucocyte expression in cholesterol carriers (ATP-binding cassette transporter ABCA1, ABCG1), were determined before any medication intervention. The data of each patient were analyzed using univariate logistic regression and are expressed by HR, 95%CI [5th–95th]. All these parameters were explored with survival parameters using Cox regression analyses. Results: Overall survival (OS) and invasive disease-free survival (iDFS) were significantly longer for the women without metabolic syndrome with HR 4.7 [1.11–19.92] and p = 0.036, and 3.58 [1.23–10.44] and p = 0.019, respectively. The expression of ABCG1 in peripheral leucocytes, an ATP-binding cassette transporter involved in cholesterol and phospholipid trafficking, is significantly associated with iDFS (1.38 [1.1–1.9], p = 0.0048). MS is associated with more pejorative survival parameters in early-stage breast cancer. Paraoxonase (or PON) activities differ according to PON gene polymorphism, but also diet. A link between PON activities and survival parameters was suggested and needs to be clarified. Conclusions: This study emphasizes the link between survival parameters of early-stage breast cancer, metabolic syndrome, and some parameters related to lipid metabolism.